Skip to main content
OpenTrials

Clinical trial condition

Gastric Adenocarcinoma

Explore clinical trials studying Gastric Adenocarcinoma. Study availability and eligibility vary by location and protocol.

200 public trials 62 recruiting studies
Refine in advanced search Browse all conditions

Gastric Adenocarcinoma trial results

Completed

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

NCT03365791

Conditions
Adenocarcinoma Of Esophagus, Advanced Well-differentiated Neuroendocrine Tumors, Bronchial Neoplasms, +28 more
Locations
  • California Pacific Medical Center Drug Shipment (2) San Francisco, California, United States
  • Hematology Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States
  • University Cancer and Blood Center, LLC Athens, Georgia, United States
  • Northwestern University Medical School Chicago, Illinois, United States
View all 20 locations
View Trial Details
Completed

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

NCT01631552

Conditions
Adenocarcinoma, Adnexal Diseases, Astrocytoma, +78 more
Locations
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Helen F. Graham Cancer Center Newark, Delaware, United States
  • MD Anderson Cancer Center Orlando (UF Health Cancer Center) Orlando, Florida, United States
View Trial Details
Completed

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

NCT02082210

Conditions
Adenocarcinoma, Advanced Cancer, Bronchial Neoplasms, +31 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Tennessee Oncology PLLC Nashville, Tennessee, United States
View Trial Details
Completed

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02864381

Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Locations
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Chicago, Illinois, United States
  • Fort Wayne, Indiana, United States
View all 34 locations
View Trial Details
Completed

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

NCT02443883

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Adenocarcinoma, +7 more
Locations
  • Arizona Clinical Research Center Tucson, Arizona, United States
  • USC Norris Cancer Hospital Los Angeles, California, United States
  • Carolinas Medical Center Charlotte, North Carolina, United States
  • Oklahoma Cancer Specialists & Research Institute, LLC Tulsa, Oklahoma, United States
View all 45 locations
View Trial Details
Completed

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

NCT02514551

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Adenocarcinoma, +7 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of Kansas Medical Center Westwood, Kansas, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Weill Cornell Medical College New York, United States
View all 52 locations
View Trial Details
Completed

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT02545504

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Adenocarcinoma, +6 more
Locations
  • Scripps Green Hospital La Jolla, California, United States
  • University of Southern California Los Angeles, California, United States
  • UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • Innovative Clinical Research Institute Whittier, California, United States
View all 134 locations
View Trial Details

Related conditions